Sensei Biotherapeutics (Sensei Biotherapeutics) Accounts Payable & Accrued Expense for Financial Companies

View and export this data going back to 2021. Start your Free Trial

What is Sensei Biotherapeutics Accounts Payable & Accrued Expense for Financial Companies?

Accounts Payable & Accrued Expense for Financial Companies only applies to insurance companies.

Sensei Biotherapeutics (Sensei Biotherapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sensei Biotherapeutics Inc (NAS:SNSE) » Definitions » Accounts Payable & Accrued Expense for Financial Companies

Comparable Companies

Traded in Other Exchanges

407:Germany 407:Germany

Address

1405 Research Boulevard, Suite 710, Boston, MA, USA, 02210

Website

https://www.senseibio.com

Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. The company currently has three investigational products. 1) SNS-101 is a conditionally active monoclonal antibody targeting the immune checkpoint VISTA (V-domain Ig suppressor of T-cell activation): 2) SNS-102 is a conditionally active monoclonal antibody targeting VSIG4 (V-Set and Immunoglobulin Domain Containing 4), an immune checkpoint often expressed on macrophages: 3) SNS-103 is a conditionally active monoclonal antibody targeting ENTPDase1 (ecto-nucleoside triphosphate diphosphohydrolase-1), also known as CD39.

Executives

Stephanie Krebs	officer: Chief Business Officer	C/O SENSEI BIOTHERAPEUTICS, INC., 1405 RESEARCH BLVD, SUITE 125, ROCKVILLE MD 20850
John Celebi	director, officer: President & CEO	SENSEI BIOTHERAPEUTICS, INC., 1405 RESEARCH BLVD., STE. 125, ROCKVILLE MD 20850
James Peyer	director, 10 percent owner	C/O SENSEI BIOTHERAPEUTICS, INC., 1405 RESEARCH BLVD., STE. 125, ROCKVILLE MD 20850
Cambrian Biopharma Inc	10 percent owner, other: See Remarks	228 PARK AVENUE S., #66643, NEW YORK NY 10003
Apeiron Investment Group Ltd.	10 percent owner	BLOCK A, APT.12, IL-PIAZZETTA, TOWER ROAD, SLIEMA O1 SLM1605
Presight Sensei Co-invest Fund, L.p.	other: See Explanation of Responses	340 S. LEMON AVE., # 3391, WALNUT CA 91789
Van Der Horst Edward	officer: Chief Scientific Officer	C/O SENSEI BIOTHERAPEUTICS, INC., 451 D STREET, SUITE 710, BOSTON MA 02210
Presight Co-invest Management, L.l.c.	10 percent owner	340 SOUTH LEMON AVENUE #3391, WALNUT CA 91789
Christian Angermayer	10 percent owner	BLOCK A, APT.12, IL-PIAZZETTA, TOWER ROAD, SLIEMA O1 SLM1605
Patrick Stephen Gallagher	officer: Chief Business Officer	66 HAROLD ST, BOSTON MA 02119
William R Ringo	director
Thomas G Ricks	director	H&S VENTURES LLC, 2101 EAST COAST HWY - 3RD FLOOR, CORONA DEL MAR CA 92625
Robert Hamilton Pierce	officer: Chief Scientific Officer	C/O SENSEI BIOTHERAPEUTICS, INC., 1405 RESEARCH DR.., STE. 125, ROCKVILLE MD 20850
Kristian Humer	director	C/O VIRIDIAN THERAPEUTICS, INC., 6200 LOOKOUT ROAD, BOULDER CO 80301
Jessie English	director	C/O SENSEI BIOTHERAPEUTICS, INC., 1405 RESEARCH DR., STE. 125, ROCKVILLE MD 20850